title: Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents.
abstract: Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
authors.affiliation: CRC for Diagnostic Technologies and CSIRO Health Sciences and Nutrition, Parkville, Victoria, Australia. Stewart.Nuttall@hsn.csiro.au
authors.forename: S D
authors.initials: SD
authors.lastname: Nuttall
authors.forename: R A
authors.initials: RA
authors.lastname: Irving
authors.forename: P J
authors.initials: PJ
authors.lastname: Hudson
mesh_terms: D000818:Animals; D002162:Camelus; D015195:Drug Design; D005803:Genes, Immunoglobulin / Q000235:genetics*; D006801:Humans; D007128:Immunoglobulin Fragments / Q000737:chemistry*; D007167:Immunotherapy; D012754:Sharks
chemical_list: D007128:Immunoglobulin Fragments